When ^99mTc was first applied to radiopharmaceuticals for diagnostic nuclear medicine, major efforts were focused on the development of ^99mTc complexes for excretory organs such as the liver and kidney. Over the past 30 years, a significant advance was made in technetium chemistry and radiopharmaceutical design. Now, ^99mTc radiopharmaceuticals for measuring regional cerebral and myocardial blood flow are available in clinical studies. More recently, transporter functions of the brain can also be visualized with ^99mTc radiopharmaceuticals. In this manuscript, recent advances in ^99mTc radiopharmaceuticals will be briefly reviewed.